News from novavax, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Mar 06, 2023, 16:02 ET Novavax to Participate in TD Cowen's 43rd Annual Health Care Conference

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will...

Mar 02, 2023, 17:00 ET Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company...

Feb 28, 2023, 16:02 ET Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Achieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billion Appointed John C. Jacobs as President and Chief Executive ...

Feb 21, 2023, 16:02 ET Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023

Novavax, Inc. (Nasdaq: NVAX), a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will...

Feb 13, 2023, 08:00 ET Le gouvernement des États-Unis et Novavax étendent leur partenariat et garantissent jusqu'à 1,5 million de doses supplémentaires du vaccin Novavax contre la COVID-19

Feb 13, 2023, 08:00 ET El gobierno de los Estados Unidos y Novavax extienden su alianza y aseguran hasta 1,5 millones de dosis adicionales de la vacuna de Novavax contra la COVID-19

Feb 13, 2023, 08:00 ET Governo dos EUA e Novavax ampliam parceria, garantindo até 1,5 milhões de doses adicionais da vacina contra a COVID-19 da Novavax

Feb 13, 2023, 08:00 ET El gobierno de Estados Unidos y Novavax aseguran hasta 1,5 millones de dosis más de la vacuna de la COVID-19

Feb 13, 2023, 08:00 ET Verlängerung der Partnerschaft zwischen der US-Regierung und Novavax zur Bereitstellung von bis zu 1,5 Millionen zusätzlichen Dosen des COVID-19-Impfstoffs von Novavax

Feb 13, 2023, 08:00 ET U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious...

Feb 13, 2023, 08:00 ET U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine

Jan 25, 2023, 17:00 ET Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious...

Jan 18, 2023, 08:00 ET Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious...

Jan 09, 2023, 09:00 ET Novavax Names John C. Jacobs as New President & Chief Executive Officer

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious...

Dec 30, 2022, 08:00 ET Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious...

Dec 28, 2022, 17:00 ET Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock

On December 20, 2022, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company (the "Company" or "Novavax") dedicated to developing and commercializing...

Dec 18, 2022, 17:05 ET Novavax kündigt Preis für öffentliches Stammaktienangebot in Höhe von 65 Millionen Dollar an

Dec 18, 2022, 16:04 ET Novavax gibt die Preisgestaltung seines 150-Millionen-Dollar-Angebots von Wandelschuldverschreibungen bekannt

Dec 17, 2022, 13:29 ET Novavax annonce une offre proposée de 150 millions de dollars d'obligations convertibles de premier rang

Dec 17, 2022, 13:17 ET Novavax annonce la fixation du prix de l'offre publique d'actions ordinaires pour un montant de 65 millions de dollars

Dec 16, 2022, 16:32 ET Novavax annonce une offre proposée de 125 millions de dollars d'obligations convertibles de premier rang

Dec 16, 2022, 11:38 ET Novavax anuncia valor de $65 milhões para oferta pública de ações ordinárias

Dec 16, 2022, 11:33 ET Novavax anuncia el precio de la oferta de 150 millones de dólares de bonos preferentes convertibles

Dec 16, 2022, 11:30 ET Novavax anuncia preço de $150 milhões de ofertas de títulos seniores conversíveis

Dec 16, 2022, 11:28 ET Novavax anuncia el precio de una oferta pública de 65 millones de dólares en acciones ordinarias